AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
29 févr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
Shamir Medical Center Reveals New Long-Term Results from Long COVID Study to Highlight Positive Impact on Symptoms Resulting from Hyperbaric Oxygen Therapy
15 févr. 2024 09h39 HE
|
Aviv Clinics
ORLANDO, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Today, Aviv Clinics reveals results from the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center and Tel Aviv University from...
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
08 févr. 2024 08h50 HE
|
AIM ImmunoTech Inc.
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
electroCore Expands Intellectual Property Portfolio
06 févr. 2024 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
12 déc. 2023 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID.
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
27 nov. 2023 21h00 HE
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 ...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
27 nov. 2023 09h05 HE
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
21 nov. 2023 12h00 HE
|
AIM ImmunoTech Inc.
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”)...
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
15 nov. 2023 07h30 HE
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
09 nov. 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...